New blood test could revolutionize TB treatment monitoring

NCT ID NCT07157904

Not yet recruiting Knowledge-focused Sponsor: Nagasaki University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study in Kenya will test whether a new blood test, called PATHFAST TB LAM ag, can better track how well tuberculosis (TB) treatment is working. Researchers will follow 300 adults with TB, collecting samples regularly during their 6-month treatment. The goal is to see if changes in a substance called LAM can predict treatment success or failure earlier than current methods.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PATHFAST TB LAM ag assay (a blood test for LAM, a substance from TB bacteria)
What this could lead to: If successful, this test could provide a faster, simpler way to monitor TB treatment, helping doctors catch problems early and improve recovery rates.
What could go wrong: This is an early observational study with only 300 participants, so results may not apply to all TB patients. The test's accuracy in real-world settings is still unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYCOBACTERIUM TUBERCULOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary tuberculosis tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYCOBACTERIUM TUBERCULOSIS PULMONARY TUBERCULOSES TUBERCULOSIS

Contacts and locations

Locations

Mbagathi County Referral Hospital

Nairobi, Kenya
Rhodes Chest Clinic

Nairobi, Kenya

More trials for these conditions

Other studies related to the condition(s) this trial covers.